Dana Abbott, APRN
Acute Care · Rogers, ARNPI 1164101564
Payments from drug & device makers
Across 51 payments — averaging $30.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$563
- Johnson & Johnson$159
- Novartis$139
- Regeneron Healthcare Solutions, Inc.$120
- Solventum Corporation$89
- AstraZeneca$68
- plus $398 from 15 others
What the payments were for
- Consulting fees$56337%
- Food & beverage$90459%
- Education$684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 1 | $563 |
| Johnson & Johnson | 8 | $159 |
| Novartis | 8 | $139 |
| Regeneron Healthcare Solutions, Inc. | 8 | $120 |
| Solventum Corporation | 3 | $89 |
| AstraZeneca | 1 | $68 |
| Convatec Inc. | 2 | $55 |
| Smith+Nephew | 2 | $50 |
| AbbVie | 3 | $48 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| Merck | 2 | $31 |
| Eisai Inc. | 2 | $31 |
| Kerecis Limited | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $19 |
| Mimedx Group, Inc. | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Progenics Pharmaceuticals, Inc. | 1 | $15 |
| Molnlycke Health Care US, LLC | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| Morphosys, US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBREVANT$563
How this compares
$1,535 in reported general payments places this provider in the 70th percentile of 321 acute care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 11 | $155,716 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,279 |
| Olanzapine | 26 | $461 |
| Gentamicin Sulfate | 11 | $459 |
| Fluconazole | 12 | $195 |
| Doxycycline Hyclate | 22 | $192 |
| Potassium Chloride | 16 | $115 |
| Ciprofloxacin Hcl | 12 | $71 |
| Levofloxacin | 14 | $58 |
| Prednisone | 12 | $41 |
Paid to pharmacies, not to this prescriber.
Other acute care in Rogers
- Diana TorresRogers$4K
- Jill AveryLittle Rock$117K
- Lynn FrazierLittle Rock$106K
- Cheryl WalshSpringdale$101K
- Beverly BaxterLittle Rock$95K
- Diane GlendinningLittle Rock$26K
- Beth CrowderLittle Rock$25K
- Carmen Paniagua TorresLittle Rock$21K
- Jennifer HocuttHot Springs$15K
- Shana KloskeLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.